ANP32E drives vulnerability to ATR inhibitors by inducing R-loops-dependent transcription replication conflicts in triple negative breast cancer

Nat Commun. 2025 May 17;16(1):4602. doi: 10.1038/s41467-025-59804-0.

Abstract

Oncogene-induced replicative stress (RS) drives tumor progression by disrupting genome stability, primarily through transcription-replication conflicts (TRCs), which promote R-loop accumulation and trigger the DNA damage response (DDR). In this study, we investigate the role of chromatin regulators in exacerbating TRCs and R-loop accumulation in cancer. We find that in breast cancer patients, the simultaneous upregulation of MYC and the H2A.Z-specific chaperone ANP32E correlates with increased genomic instability. Genome-wide analyses reveal that ANP32E-driven H2A.Z turnover alters RNA polymerase II processivity, leading to the accumulation of long R-loops at TRC sites. Furthermore, we show that ANP32E overexpression enhances TRC formation and activates an ATR-dependent DDR, predisposing cancer cells to R-loop-mediated genomic fragility. By exploiting the vulnerability of ANP32E-expressing cancer cells to ATR inhibitors, we find that tumors relied on this DDR pathway, whose inhibition halts their pro-metastatic capacity. These findings identify ANP32E as a key driver of TRC-induced genomic instability, indicating ATR inhibition as a potential therapeutic strategy for ANP32E-overexpressing tumors.

MeSH terms

  • Animals
  • Ataxia Telangiectasia Mutated Proteins* / antagonists & inhibitors
  • Ataxia Telangiectasia Mutated Proteins* / genetics
  • Ataxia Telangiectasia Mutated Proteins* / metabolism
  • Cell Line, Tumor
  • DNA Damage
  • DNA Replication* / drug effects
  • DNA Replication* / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Genomic Instability
  • Histones / metabolism
  • Humans
  • Mice
  • Nuclear Proteins* / genetics
  • Nuclear Proteins* / metabolism
  • Proto-Oncogene Proteins c-myc / genetics
  • Proto-Oncogene Proteins c-myc / metabolism
  • R-Loop Structures* / genetics
  • RNA Polymerase II / metabolism
  • Transcription, Genetic*
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / genetics
  • Triple Negative Breast Neoplasms* / metabolism
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Ataxia Telangiectasia Mutated Proteins
  • ATR protein, human
  • Nuclear Proteins
  • Histones
  • RNA Polymerase II
  • Proto-Oncogene Proteins c-myc